Involvement of Ca$^{2+}$ Signaling in the Synergistic Effects between Muscarinic Receptor Antagonists and $\beta_2$-Adrenoceptor Agonists in Airway Smooth Muscle

Kentaro Fukunaga, Hiroaki Kume, Tetsuya Oguma, Wataru Shigemori, Yuji Tohda, Emiko Ogawa and Yasutaka Nakano

1 Division of Respiratory Medicine, Department of Internal Medicine, Shiga University of Medical Science, Seta, Tsukinowa-cho, Otsu, Shiga 520-2192, Japan; fukuken@belle.shiga-med.ac.jp (K.F.); oguma@belle.shiga-med.ac.jp (T.O.); nitori@belle.shiga-med.ac.jp (W.S.); eogawa@belle.shiga-med.ac.jp (E.O.); nakano@belle.shiga-med.ac.jp (Y.N.)

2 Department of Respiratory Medicine and Allergology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osakasayama, Osaka 589-8511, Japan; tohda@med.kindai.ac.jp

* Correspondence: hkume@med.kindai.ac.jp; Tel.: +81-72-366-0221 (ext. 3602); Fax: +81-72-367-7772

Abstract: Long-acting muscarinic antagonists (LAMAs) and short-acting $\beta_2$-adrenoceptor agonists (SABAs) play important roles in remedy for COPD. To propel a translational research for development of bronchodilator therapy, synergistic effects between SABAs with LAMAs were examined focused on Ca$^{2+}$ signaling using simultaneous records of isometric tension and F340/F380 in fura-2-loaded tracheal smooth muscle. Glycopyrronium (3 nM), a LAMA, modestly reduced methacholine (1 µM)-induced contraction. When procaterol, salbutamol and SABAs were applied in the presence of glycopyrronium, relaxant effects of these SABAs are markedly enhanced, and percent inhibition of tension was much greater than the sum of those for each agent and those expected from the BI theory. In contrast, percent inhibition of F340/F380 was not greater than those values. Bisindolylmaleimide, an inhibitor of protein kinase C (PKC), significantly increased the relaxant effect of LAMA without reducing F340/F380. Iberiotoxin, an inhibitor of large-conductance Ca$^{2+}$-activated K$^+$ (K$\text{Ca}$) channels, significantly suppressed the effects of these combined agents with reducing F340/F380. In conclusion, combination of SABAs with LAMAs synergistically enhances inhibition of muscarinic contraction via decreasing both Ca$^{2+}$ sensitization mediated by PKC and Ca$^{2+}$ dynamics mediated by K$\text{Ca}$ channels. PKC and K$\text{Ca}$ channels may be molecular targets for cross talk between $\beta_2$-adrenoceptors and muscarinic receptors.

Keywords: cross talk; Ca$^{2+}$ dynamics; Ca$^{2+}$ sensitization; large-conductance Ca$^{2+}$-activated K$^+$ channel; protein kinase C; tracheal smooth muscle; tiotropium; procaterol; COPD

1. Introduction

Chronic obstructive pulmonary disease (COPD) is characterized by irreversible narrowing of the small airways and decreased elastic recoil of the lung due to destruction of the alveoli [1,2]. As a result, hyperinflation occurs, causing dyspnea during exercise, and decreasing exercise tolerability in patients with COPD [3,4]. Although the fundamental pathophysiology of COPD is considered to be neutrophilic inflammation in the airways, there are currently no specific anti-inflammatory agents for this disease. Inhaled bronchodilators, such as muscarinic receptor antagonists and $\beta_2$-adrenoceptor agonists, are widely used clinically to reduce symptoms (shortness of breath, wheezing), augment lung function (forced expiratory volume in 1 second, inspiratory capacity), and reduce exacerbations and hospitalizations, improving quality of life.
Inhalation of muscarinic receptor antagonists \[5,6\] and \(\beta_2\)-adrenoceptor agonists \[7,8\] is used in the management of COPD. However, a single type of bronchodilator may be insufficiently effective for this disease. A recent COPD guideline states that a combination of bronchodilators of different pharmacological classes may improve effectiveness and decrease the risk of adverse reactions compared to increasing the dose of a single bronchodilator \[2\]. Long-acting \(\beta_2\)-adrenoceptor agonists (LABAs) and long-acting muscarinic receptor antagonists (LAMAs) are two types of bronchodilators widely used as therapy for this disease, and there is a pharmacological rationale for the use of a combination of these agents \[9–12\]. Recent studies in patients with COPD have also demonstrated that the LABA/LAMA combination is more effective in improving symptoms and lung function, and reducing exacerbations, than monotherapy with either agent \[13–16\].

In airway smooth muscle, LABAs and LAMAs act synergistically, enhancing inhibition of muscarinic contraction more than the sum of the effects of each agent \[9,10\]. Cross talk between these two receptors may contribute to this synergistic effect in airway smooth muscle. Large-conductance \(\text{Ca}^{2+}\)-activated \(\text{K}^+\) (\(\text{K}^{\text{Ca}}\)) channels are regulated by \(G_s\) proteins coupled to \(\beta_2\)-adrenoceptors \[17–19\] and \(G_i\) proteins coupled to muscarinic M\(_2\) receptors \[18–21\]. Since the functional antagonism between \(\beta_2\)-adrenoceptor and muscarinic receptor action converges on \(K^{\text{Ca}}\) channels \[22\], this synergism may be caused by \(\text{Ca}^{2+}\) dynamics (changes in concentration of intracellular \(\text{Ca}^{2+}\)) via \(K^{\text{Ca}}\) channel activity (Figure 1) \[23,24\]. However, little is currently known about the involvement of \(\text{Ca}^{2+}\) sensitization in the mechanism underlying this synergy between these two \(G\) protein-coupled receptors (GPCRs), such as \(\beta_2\)-adrenoceptors and muscarinic receptors.

Various contractile agents such as acetylcholine cause smooth muscle contraction via GPCRs. Airway smooth muscle tone is regulated by \(\text{Ca}^{2+}\) dynamics and \(\text{Ca}^{2+}\) sensitization. The \(\text{Ca}^{2+}\) dynamics is a mechanism of airway smooth muscle contraction via activation of a \(\text{Ca}^{2+}/\text{calmodulin}\)-dependent myosin light chain kinase and increase intracellular \(\text{Ca}^{2+}\) concentration via a \(\text{Ca}^{2+}\) influx through \(\text{Ca}^{2+}\) channels (\(\text{Ca}^{2+}\)-dependent contraction). In contrast, since Phosphorylation (inactivation) of myosin phosphatase (MP) causes contraction as intracellular \(\text{Ca}^{2+}\) level unchanged, MP inhibition contributes to \(\text{Ca}^{2+}\) sensitization (\(\text{Ca}^{2+}\)-independent contraction) \[25\]. MP is phosphorylated by Rho-kinase, which is an effector of the small \(G\) protein RhoA \[26–28\] and by C-kinase-potentiated protein phosphatase-1 inhibitor (CPI-17), which is another potential mediator regulated by protein kinase C (PKC) (Figure 1) \[29–31\]. \(\text{Ca}^{2+}\) signaling in airway smooth muscle plays an essential role in the pathophysiology of asthma and COPD \[9,10,32–37\].

Inhalation of rapid- and short-acting bronchodilators such as short-acting \(\beta_2\)-adrenoceptor agonists (SABAs) is useful for symptom relief in patients with COPD. Because of the synergistic effect of these two agents on bronchodilation, pre-administration of LAMAs may be effective for as-needed use of SABAs, such as salbutamol and procaterol. Therefore, there is a need for the development of pharmacological treatments for COPD that exploit the synergistic effects between LAMAs and SABAs. This study was designed to determine whether procaterol and salbutamol (SABAs) and glycopyrronium (a LAMA) act synergistically to relax contracted airway smooth muscle. We promoted this study on the assumption of involvement of the major pathway in \(\text{Ca}^{2+}\) dynamics and \(\text{Ca}^{2+}\) sensitization, which play a key role of contraction of airway smooth muscle. In particular, mechanisms underlying this phenomenon were examined with a focus on \(\text{Ca}^{2+}\) signaling, specifically \(\text{Ca}^{2+}\) dynamics mediated by \(K^{\text{Ca}}\) channels and \(\text{Ca}^{2+}\) sensitization mediated by Rho-kinase and PKC in airway smooth muscle. The functional antagonism between \(\beta_2\)-adrenergic and muscarinic action converges on \(K^{\text{Ca}}\) channel currents, and Rho-kinase and PKC play key role in muscarinic contraction of airway smooth muscle.
Figure 1. The intracellular mechanisms of the synergistic effects between β2-adrenoceptor agonists and muscarinic receptor antagonists. Not only Ca2+ sensitization but also Ca2+ dynamics contributes to the synergistic effect of β2-adrenoceptor agonists and muscarinic receptor antagonists (cross talk between β2-adrenoceptors and muscarinic receptors). In Ca2+ dynamic, Ca2+ influx by VDCE is involved in this phenomenon. VDCE is regulated by membrane potential via KCa channel activity, which is augmented by Ga coupled to β2-adrenoceptor, in contrast, attenuated by Gs coupled to muscarinic M2 receptors (dual regulation by G proteins). Increased intracellular Ca2+ concentration causes contraction by activation of MLCK via Ca2+ /CAM processes (Ca2+-dependent contraction). In Ca2+ sensitization, PKC is involved in this phenomenon. PKC is activated by muscarinic M3 receptors. PKC inhibits MP activity via CPI-17 processes. Inactivation of MP causes contraction by increased sensitivity to intracellular Ca2+ (Ca2+-independent contraction). CPI-17 MP is activated by PKC, in contrast, inhibited by PKA. KCa channels and CPI-17 are key molecules for this synergistic effect via the cross talk between these two receptors. This synergism may be caused by Ca2+ dynamics (tone with changes in concentration of intracellular Ca2+) via KCa channel activity reciprocally regulated by G proteins (Ga and Gs), and caused by Ca2+ sensitization (tone without changes in concentration of intracellular Ca2+) via CPI-17 reciprocally regulated by protein kinases (PKA and PKC). KCa: large-conductance Ca2+-activated K+ channels. VDCE: voltage-dependent Ca2+ entry. ACh: acetylcolin, LAMA: long-acting muscarinic receptor antagonist. AC: adenylate cyclase. PKA: protein kinase A. PKC: protein kinase C. CPI-17: C-kinase-potentiated protein phosphatase-1 inhibitor. CaM: calmodulin. MLCK: myosin light chain kinase. MP: myosin phosphatase.

2. Results

2.1. Inhibitory Effects of Procaterol, Salbutamol, and Glycopyrronium on Tension and Intracellular Ca2+ Concentration in Contracted Muscle

When procaterol (0.1–10 nM) and salbutamol (1–100 nM) were cumulatively applied to strips of tracheal smooth muscle pre-contracted with MCh (always 1 µM throughout this study), both inhibited MCh-induced contraction and reduced F340/F380 in a concentration-dependent manner. However, when almost complete relaxation was achieved at the maximum concentrations tested (procaterol, 10 nM; SB, 100 nM), F340/F380 was still higher than at the basal level (Figure 2a,b). The concentration–inhibition curve of procaterol and salbutamol for MCh-induced tension was significantly dissociated from the curve for F340/F380 (n = 5, p < 0.05), and the reduction in tension was significantly greater than the reduction in F340/F380 at each concentration ≥1 nM (procaterol) and ≥10 nM (salbutamol) (Figure 2c,d). However, when glycopyrronium (0.3–10 nM) was cumulatively applied to the strips of tracheal smooth muscle in the same way, glycopyrronium inhibited MCh-induced contraction and reduced F340/F380 in a concentration-dependent manner.
The concentration–inhibition curve of glycopyrronium for MCh-induced tension was also dissociated from the curve for F340/F380 ($n = 5$, $p < 0.05$), but the reduction in F340/F380 was significantly greater than that in tension at each concentration (0.1–3 nM) (Figure 3).

Figure 2. Involvement of Ca$^{2+}$ dynamics and Ca$^{2+}$ sensitization in the relaxant effect of β$_2$-adrenoceptor agonists. (a,b) Typical samples of continuous recording of tension and F340/F380 demonstrating the inhibitory effect of procaterol (0.1–30 nM) (a) and salbutamol (1–100 nM) (b) on MCh (1 μM)-induced smooth muscle contraction; (c,d) Concentration–response curve for procaterol (0.1–10 nM) (c) and salbutamol (1–100 nM) (d) in tension (□) and F340/F380 (■) in 1 μM MCh-precontracted smooth muscle. Resting state tension and F340/F380 were taken as 0%, and those in each MCh-stimulated state were taken as 100%. MCh, methacholine; PRO, procaterol; SB, salbutamol. **** $p < 0.0001$; *** $p < 0.001$; ** $p < 0.01$; * $p < 0.05$.

Figure 3. Involvement of intracellular Ca$^{2+}$ dynamics in the relaxant effect of glycopyrronium. (a) Typical sample of continuous recording of tension and F340/F380 demonstrating the inhibitory effect of glycopyrronium (0.3–10 nM) on MCh (1 μM)-induced contraction; (b) Concentration–response curve for glycopyrronium (0.1–10 nM) in tension (□) and F340/F380 (■) induced by MCh (1 μM). GB, glycopyrronium bromide; MCh, methacholine. ** $p < 0.01$; * $p < 0.05$. 

Int. J. Mol. Sci. 2016, 17, 1590 4 of 18
2.2. Effects of Procaterol and Salbutamol Combined with Glycopyrronium on Tension and Intracellular Ca\(^{2+}\) Concentration in Contracted Muscle

Glycopyrronium (3 nM) reduced MCh-induced tension and F340/F380 by 7.2% ± 4.5% and 23.6% ± 4.0% (n = 5), respectively; procaterol (1 nM) reduced them by 37.0% ± 9.1% and 32.9% ± 5.4% (n = 5), respectively. When procaterol (1 nM) was applied to the MCh-precontracted strips in the presence of glycopyrronium (3 nM), inhibition of contraction and decrease in F340/380 were markedly enhanced, to 73.9% ± 8.2% and 55.3% ± 1.5% (n = 5), respectively (Figure 4a,b). Under these conditions, inhibition of contraction was considerably greater than the sum of the effects of each agent (44.2% ± 10.3%, n = 5, p < 0.0001; Figure 4b), and the values predicted by the Bliss independence (BI) theory (41.5% ± 8.8%, n = 5, p < 0.0001; Figure 4b). A detailed discussion of the BI theory can be found in the method section. In contrast, reduction of F340/F380 was not significantly greater than the sum of the effect of each agent (59.1% ± 8.7%, n = 5; Figure 4b) or the expected value by BI theory (50.4% ± 6.2%, n = 5; Figure 3b). Next, we lowered the concentration of procaterol to 0.1 and 0.3 nM. At 0.1 nM, procaterol inhibited MCh-induced contraction by 3.4% ± 2.4% and reduced F340/F380 by 4.5% ± 3.2% (n = 5). However, in the presence of glycopyrronium (3 nM), those values were augmented to 31.2% ± 13.8% and 26.9% ± 8.1% (n = 5), respectively (Figure 4c). Under these conditions, percent inhibition of contraction was also much greater than the sum of the values for each agent (10.6% ± 5.6%, n = 5, p < 0.001; Figure 4c) and the expected value (10.3% ± 5.4%, n = 5, p < 0.01; Figure 4c). In contrast, percent inhibition of F340/F380 was not increased significantly more than the sum of the values for each agent (30.8% ± 5.9%, n = 5; Figure 4c) or the expected values (29.6% ± 5.2%, n = 5; Figure 4c). Percent inhibition of contraction and F340/F380 for procaterol (0.3 nM) in MCh-precontracted tissue were 13.1% ± 11.0% and 11.4% ± 3.6% (n = 5), respectively. When procaterol (0.3 nM) was applied in the presence of glycopyrronium (3 nM), those values were augmented to 46.0% ± 7.7% and 38.5% ± 9.7% (n = 5), respectively (Figure 4d). Percent inhibition of contraction by the two agents in combination was considerably greater than the sum of the values for each agent (20.3% ± 11.2%, n = 5, p < 0.001; Figure 4d) and the expected value (19.4% ± 10.4%, n = 5, p < 0.001; Figure 4d). In contrast, percent inhibition of F340/F380 was not significantly greater for the combination than the sum of the values for each agent (41.1% ± 5.3%, n = 5; Figure 4d) or the expected value (36.5% ± 2.3%, n = 5; Figure 4d).

Furthermore, we examined the interaction between glycopyrronium and salbutamol, another SABA, in the same way. Salbutamol (10 nM) inhibited MCh-induced contraction and reduced F340/F380 by 60.8% ± 10.6% and 59.8% ± 8.0% (n = 5), respectively. When salbutamol (10 nM) was applied in the presence of glycopyrronium (3 nM), contraction was inhibited by 85.4% ± 6.2% and F340/F380 was reduced by 60.4% ± 8.4% (n = 5; Figure 5a,b). The inhibition of contraction by salbutamol (10 nM) combined with glycopyrronium (3 nM) was significantly greater than the sum of the values for each agent (68.0% ± 9.3%, n = 5, p < 0.01; Figure 5b) and the expected value by BI theory (63.8% ± 8.9%, p < 0.01; Figure 4b). However, the combination of agents decreased F340/F380 much by less than the sum of the values for each agent (86.1% ± 6.3%, n = 5, p < 0.0001; Figure 5b) or the expected value (70.5% ± 5.0%, p < 0.05; Figure 5b). The inhibitory effects of salbutamol (3 nM) on these measures were 24.6% ± 14.7% and 29.5% ± 7.0% (n = 5), respectively. When salbutamol (3 nM) was applied in the presence of glycopyrronium (3 nM), contraction was inhibited by 56.7% ± 15.3% and F340/F380 was reduced by 45.7% ± 10.9% (n = 5; Figure 5c). Contraction was inhibited more than the sum of the effects of each agent (31.8% ± 13.7%, n = 5, p < 0.01; Figure 5c) and the expected value (30.2% ± 12.7%, p < 0.01; Figure 5c), but reduction of F340/F380 was not significantly greater than the sum the effects of each agent (55.8% ± 8.1%, n = 5; Figure 5c) or expected value (48.1% ± 5.9%; Figure 5c).
strips in the presence of tiotropium (1 nM), inhibition of contraction and decrease in F340/F380 were augmented to 42.6% ± 16.4% and 26.0% ± 14.4% (n = 5, Figure 6b), respectively. Under these conditions, percent inhibition of contraction was also much greater than the sum of the effects of each agent (44.1% ± 7.6%, n = 5, p < 0.05, Figure 6b), but that value was not significant greater than the expected value (38.1% ± 3.8%, n = 5, Figure 6b). At 0.3 nM procaterol, in the presence of tiotropium (1 nM), inhibition of contraction and decrease in F340/F380 were augmented to 42.6% ± 16.4% and 26.0% ± 14.4% (n = 5, Figure 6c), respectively. Under these conditions, percent inhibition of contraction was also much greater than the sum of the values for each agent (16.0% ± 12.4%, n = 4, p < 0.05; Figure 6c) and the expected value (17.4% ± 14.8%, n = 4, p < 0.05; Figure 6c). In contrast,

Figure 4. Effects of combination of procaterol and glycopyrronium on tension and intracellular Ca$^{2+}$ concentration induced by muscarinic activation. (a) Typical traces of tension (upper side and F340/F380 (lower side) showing the inhibitory effect of procaterol (1 nM) in the presence of glycopyrronium (3 nM) on MCh (1 μM)-induced contraction; (b–d) Percent inhibition of tension (white columns) and F340/F380 (black columns) in 1 μM MCh-induced contraction under the experimental conditions of 1 nM procaterol (b); 0.1 nM procaterol (c); and 0.3 nM procaterol (d) in the presence of glycopyrronium (3 nM). Left, sum of percent inhibition of tension and F340/F380 by the two agents; Center, BI, expected percent inhibition of tension and F340/F380 calculated by the Bliss independence theory; Right, percent inhibition of tension and F340/F380 with the two agents in combination. PRO, procaterol; GB, glycopyrronium bromide; MCh, methacholine. **** p < 0.0001; ** p < 0.01; * p < 0.05; Figure 6c). In contrast, percent inhibition of F340/F380 was not increased significantly more than the sum of the effects of each agent (39.9% ± 7.8%, n = 5, Figure 6b), and the expected value (38.9% ± 7.9%, n = 5, p < 0.05, Figure 6b), but that value was not significant greater than the expected value (38.9% ± 7.9%, n = 5, p < 0.01; Figure 6d). In contrast, percent inhibition of tension was considerably greater than the sum of the effects of each agent (55.6% ± 7.1% and 35.5% ± 5.5% (n = 5), respectively (Figure 6a,b). Under these conditions, inhibition of contraction was markedly enhanced, to 55.6% ± 7.1% and 35.5% ± 5.5% (n = 5), respectively (Figure 6a, b).

2.3. Effects of Procaterol Combined with Tiotropium on Tension and Intracellular Ca$^{2+}$ Concentration in Contracted Muscle

We investigated whether the same synergistic effect was shown when tiotropium administered in combination with procaterol.

Tiotropium (1 nM) reduced MCh-induced tension and F340/F380 by 2.9% ± 3.1% and 11.3% ± 3.6% (n = 5), respectively. When procaterol (1 nM) was applied to the MCh-precontracted strips in the presence of tiotropium (1 nM), inhibition of contraction and decrease in F340/F380 were markedly enhanced, to 55.6% ± 7.1% and 35.5% ± 5.5% (n = 5), respectively (Figure 6a,b). Under these conditions, inhibition of contraction was considerably greater than the sum of the effects of each agent (39.9% ± 7.8%, n = 5, p < 0.01; Figure 6b), and the expected value (38.9% ± 7.9%, n = 5, p < 0.01; Figure 6b). In contrast, reduction of F340/F380 was significantly greater than the sum of the effect of each agent (44.1% ± 7.6%, n = 5, p < 0.05, Figure 6b), but that value was not significant greater than the expected value (38.1% ± 3.8%, n = 5, Figure 6b). At 0.3 nM procaterol, in the presence of tiotropium (1 nM), inhibition of contraction and decrease in F340/F380 were augmented to 42.6% ± 16.4% and 26.0% ± 14.4% (n = 5, Figure 6c), respectively. Under these conditions, percent inhibition of contraction was also much greater than the sum of the values for each agent (16.0% ± 12.4%, n = 4, p < 0.05; Figure 6c) and the expected value (17.4% ± 14.8%, n = 4, p < 0.05; Figure 6c). In contrast,
percent inhibition of F340/F380 was not increased significantly more than the sum of the values for each agent (22.6% ± 3.2%, n = 4; Figure 6c) or the expected values (21.4% ± 2.9%, n = 4).

Figure 5. Effects of salbutamol and glycopyrronium in combination on tension and intracellular Ca\textsuperscript{2+} concentration induced by muscarinic activation. (a) Typical sample record of tension (upper side) and F340/F380 (lower side) showing the inhibitory effect of salbutamol (10 nM) in the presence of glycopyrronium (3 nM) against 1 μM MCh-induced contraction; (b,c) Percent inhibition of tension (white columns) and F340/F380 (black columns) in 1 μM MCh-precontracted tissue incubated with 3 nM salbutamol (b) and 10 nM salbutamol (c) in the presence of glycopyrronium (3 nM). Left, sum of percent inhibition of tension and F340/F380 by the two agents; Center, expected percent inhibition of tension and F340/F380 calculated by the Bliss independence theory; Right, percent inhibition of tension and F340/F380 with the two agents in combination. SB, salbutamol; GB, glycopyrronium bromide; MCh, methacholine; BI, Bliss independence. **** p < 0.0001; ** p < 0.01; * p < 0.05.

2.4. Role of Ca\textsuperscript{2+} Sensitization in the Combined Effects of Procaterol and Glycopyrronium

From results of our experiments (Figures 4–6), synergistic effect of LAMAs and SABAs were involved not only Ca\textsuperscript{2+} dynamics but also Ca\textsuperscript{2+} sensitization. Therefore, we investigated which RhoA/Rho kinase or PKC processes were involved more strongly in this synergistic effect.

Bisindolylmaleimide (10 μM), a potent inhibitor of PKC, caused modest decreases in MCh-induced tension (2.7% ± 3.7%, n = 5) and F340/F380 (14.0% ± 6.6%, n = 5; Figure 7b, left panel), as did 3 nM glycopyrronium (7.2% ± 4.5% and 26.3% ± 4.0%, respectively; see Figures 3 and 4). When glycopyrronium (3 nM) was applied with bisindolylmaleimide (10 μM), contraction was inhibited by 20.4% ± 10.7% and F340/F380 was reduced by 19.9% ± 9.7% (n = 5; Figure 7b, right panel). The relaxant effect of glycopyrronium was increased in the presence of bisindolylmaleimide, and the combination was more effective than the sum of the values for each agent (Figure 7b; p < 0.01). In contrast, the inhibitory effect of glycopyrronium on F340/F380 was not increased by bisindolylmaleimide, and was not greater in combination than the sum of the values for each agent (Figure 7b). In tension and F340/F380, the effects of adding bisindolylmaleimide to
When glycopyrronium (3 nM) was applied with Y-27632 (1 µM) in the presence of Y-27632 was markedly greater than in its absence (see Figures 4 and 5). Percent inhibition of F340/F380 for procaterol (0.3 nM) was applied with glycopyrronium (3 nM) in the presence of Y-27632 (1 µM) against 1 nM procaterol (3 nM against 1 µM MCh-induced contraction; (b,c) Percent inhibition of tension (white columns) and F340/F380 (black columns) in 1 µM MCh-precontracted tissue incubated with 1 nM procaterol (b, n = 5) and 0.3 nM procaterol (c, n = 4) in the presence of tiotropium (1 nM). Left, sum of percent inhibition of tension and F340/F380 by the two agents; Center, expected percent inhibition of tension and F340/F380 calculated by the Bliss independence theory; Right, percent inhibition of tension and F340/F380 with the two agents in combination. PRO, procaterol; TIO, tiotropium; MCh, methacholine; BI, Bliss independence. ** p < 0.01; * p < 0.05.

When procaterol (0.3 nM) and glycopyrronium (3 nM) were applied together in the presence of bisindolylmaleimide (10 µM), percent inhibition of tension was almost the same as in the absence of bisindolylmaleimide (Figure 7c). However, reduction of F340/F380 by procaterol with glycopyrronium in the presence of bisindolylmaleimide was markedly less than in its absence (p < 0.01; Figure 7c). Y-27632 (1 µM), a selective inhibitor of Rho-kinase, caused small decreases in MCh-induced tension (5.1% ± 4.1%, n = 5) and F340/F380 (5.0% ± 6.8%, n = 5; Figure 8a; left panel). When glycopyrronium (3 nM) was applied with Y-27632 (1 µM), contraction was reduced by 12.0% ± 4.9% (n = 5) and F340/F380 by 26.5% ± 8.9% (n = 5; Figure 8a, right panel). The relaxant effect of glycopyrronium in the presence of Y-27632 was greater than without it, but the combined effect was not significantly greater than the sum of the effects of each agent (Figure 8a). Reduction in F340/F380 by glycopyrronium was also not significantly greater in the presence of Y-27632 than the sum of each agent’s effects (Figure 8a). Furthermore, the effect of adding Y-27632 to glycopyrronium on MCh-induced tension and F340/F380 was not consistent with that of adding procaterol and salbutamol to glycopyrronium (see Figures 4 and 5). When procaterol (0.3 nM) was applied with glycopyrronium (3 nM) in the presence of Y-27632 (1 µM), inhibition of MCh-induced contraction was almost the same as in the absence of Y-27632 (Figure 8b). Percent inhibition of F340/F380 for procaterol with glycopyrronium in the presence of Y-27631 was markedly greater than in its absence (p < 0.05; Figure 8b).
when salbutamol (10 nM) and glycopyrronium (3 nM) were applied in the same way, values of percent inhibition in contraction and F340/F380 by salbutamol (10 nM) with glycopyrronium (3 nM) was applied with glycopyrronium (3 nM) in the presence of iberiotoxin (30 nM), inhibition of contraction and F340/F380 were markedly decreased, to 34.7% ± 14.6% (p < 0.001) and 32.2% ± 10.8% (p < 0.01), respectively, compared to the values in the absence iberiotoxin (Figure 9b). Moreover, when salbutamol (10 nM) and glycopyrronium (3 nM) were applied in the same way, values of percent inhibition in contraction and F340/F380 by salbutamol (10 nM) with glycopyrronium (3 nM) in the presence of iberiotoxin (30 nM) were also markedly decreased to 36.5% ± 8.8% (p < 0.001) and 36.2% ± 19.6% (p < 0.05), respectively, compared to those values in the absence of iberiotoxin (Figure 9c).

2.5. Role of Large-Conductance Ca2+-Activated K+ Channels in Ca2+ Dynamics due to Procaterol and Salbutamol with Glycopyrronium

Described above, KCa channel activity plays an important role in the functional antagonism between β2-adrenoceptors and muscarinic receptors [22]. Therefore, we investigated whether KCa channel was involved in synergistic effect between LAMA and SABAs. In the presence of iberiotoxin, a selective antagonist of KCa channels, procaterol or salbutamol with glycopyrronium was applied to MCh-precontracted tissue (Figure 9a). Iberiotoxin (30 nM) caused modest increases in MCh-induced tension and F340/F380, to 111.5% ± 3.6% and 126.5% ± 13.4%, respectively. When procaterol (0.3 nM) and glycopyrronium (3 nM) in the presence of iberiotoxin (30 nM), inhibition of contraction and F340/F380 were markedly decreased, to 34.7% ± 14.6% (p < 0.001) and 32.2% ± 10.8% (p < 0.01), respectively, compared to the values in the absence iberiotoxin (Figure 9b). Moreover, when salbutamol (10 nM) and glycopyrronium (3 nM) were applied in the same way, values of percent inhibition in contraction and F340/F380 by salbutamol (10 nM) with glycopyrronium (3 nM) in the presence of iberiotoxin (30 nM) were also markedly decreased to 36.5% ± 8.8% (p < 0.001) and 36.2% ± 19.6% (p < 0.05), respectively, compared to those values in the absence of iberiotoxin (Figure 9c).
Figure 8. Y-27632-induced Ca$^{2+}$ sensitization is not involved in synergy between β$_2$-adrenoceptor agonists and muscarinic receptor antagonists. In each panel, percent inhibition of tension is represented by white columns, and F340/F380 is represented by black columns. (a) Left, percent inhibition of tension and F340/F380 with Y-27632 (1 μM); Center, sum of percent inhibition of tension and F340/F380 with Y-27632 (1 μM) and glycopyrronium (3 nM); Right, percent inhibition of tension and F340/F380 with combination of Y-27632 (1 μM) and glycopyrronium (3 nM); (b) Left, sum of percent inhibition of tension and F340/F380 with procaterol (0.3 nM) and glycopyrronium (3 nM); Center, percent inhibition of tension and F340/F380 with combination of procaterol (0.3 nM) and glycopyrronium (3 nM); Right, percent inhibition of tension and F340/F380 with combination of procaterol (0.3 nM) and glycopyrronium (3 nM) in the presence of Y-27632 (1 μM). GB, glycopyrronium bromide; PRO, procaterol; MCh, methacholine. *** $p < 0.001$; ** $p < 0.01$; * $p < 0.05$.

Figure 9. Involvement of large-conductance Ca$^{2+}$-activated K$^+$ channel in synergy between β$_2$-adrenoceptor agonists and muscarinic receptor antagonists. (a) Typical record of tension (upper side) and F340/F380 (lower side) showing the inhibitory effect of a combination of procaterol (1 nM) and glycopyrronium (3 nM) in the presence of iberiotoxin (30 nM) on MCh (1 μM)-induced contraction; (b) Percent inhibition of tension (white column) and F340/F380 (black column) with combination of procaterol (1 nM) and glycopyrronium (3 nM) in the absence (left) or presence (right) of iberiotoxin (30 nM); (c) Percent inhibition of tension (white column) and F340/F380 (black column) with combination of salbutamol (10 nM) and glycopyrronium (3 nM) in the absence (left) or presence (right) of iberiotoxin (30 nM). IbTX, iberiotoxin; GB, glycopyrronium bromide; PRO, procaterol; SB, salbutamol; MCh, methacholine. **** $p < 0.0001$; *** $p < 0.001$; ** $p < 0.01$; * $p < 0.05$. 
3. Discussion

In the present study, GB (a LAMA) synergistically enhanced the inhibitory effect of procaterol and salbutamol (SABAs) on muscarinic contraction in airway smooth muscle via Ca\(^{2+}\) dynamics due to an inhibition in K\(_{Ca}\) channel activity, and Ca\(^{2+}\) sensitization due to an increase in PKC activity. These results demonstrate that this synergistic effect of combination between a SABA and a LAMA is mediated by the intracellular processes of \(\beta_2\)-adrenoceptors and muscarinic receptors shown in Figure 1. We also observed similar synergistic effects between procaterol and tiotropium (another LAMA) in airway smooth muscle (Figure 6). These results demonstrate that pre-administration of a LAMA causes a marked augmentation in the relaxant action of SABAs, and that Ca\(^{2+}\) signaling due to both Ca\(^{2+}\) dynamics and Ca\(^{2+}\) sensitization contributes to this synergistic effect (cross talk between \(\beta_2\)-adrenoceptors and muscarinic receptors). Recent reports have demonstrated that indacaterol, a LABA, synergistically augments the inhibitory effects of glycopyrronium against muscarinic contraction in airway smooth muscle \[9,10\]. Moreover, synergistic effects are similarly observed between olodaterol, another LABA, and tiotropium \[38\]. Therefore, synergistic effects against muscarinic contraction may be a ubiquitous phenomenon between \(\beta_2\)-adrenoceptor agonists and muscarinic receptor antagonists.

Ca\(^{2+}\) signaling, mediated by Ca\(^{2+}\) dynamics via various channels and by Ca\(^{2+}\) sensitization due to the inactivation of MP via RhoA/Rho-kinase and PKC/CPI-17, contributes to airway smooth muscle tone induced by contractile agents via GPCRs, and other receptors \[26–37,39–43\]. The inhibitory effect of procaterol and salbutamol on MCh-induced contraction is mediated by reducing intracellular Ca\(^{2+}\) concentration; however, the reduction in contraction is greater than the reduction in intracellular Ca\(^{2+}\) concentration (Figure 2). These results are consistent with those shown in a previous report using isoprenaline, a SABA \[43\], suggesting that procaterol and salbutamol relax airway smooth muscle by reducing both Ca\(^{2+}\) dynamics and Ca\(^{2+}\) sensitization, like isoprenaline. Conversely, glycopyrronium inhibited MCh-induced contraction while also reducing intracellular Ca\(^{2+}\) concentration, although the contraction was reduced less than intracellular Ca\(^{2+}\) concentration, unlike the SABAs in this study (Figure 3). The relationship between tension and F340/F380 for glycopyrronium was consistent with that for SKF96365, a non-selective inhibitor of Ca\(^{2+}\) influx \[43\]. These results suggest that muscarinic receptor antagonists inhibit muscarinic contraction of airway smooth muscle by reducing Ca\(^{2+}\) dynamics. The role of Ca\(^{2+}\) signaling (dynamics and sensitization) in the inhibition of muscarinic contraction is not identical between \(\beta_2\)-adrenoceptor activation and muscarinic receptor suppression (Figures 2 and 3).

We also examined the effects of a combination of SABAs with glycopyrronium on MCh-induced tension and intracellular Ca\(^{2+}\) concentration. When the SABAs procaterol (0.1–1 nM) and salbutamol (1–10 nM) were applied in the presence of glycopyrronium, the relaxant effect was greater than the sum of the effects of the equivalent concentrations of each agent (Figures 4 and 5), similar to the combined relaxant effect of indacaterol (a LABA) and glycopyrronium shown in previous reports \[9,10\]. These results demonstrate that pre-exposure to a lower concentration of glycopyrronium markedly enhances the effect of SABAs. To confirm these synergistic effects between SABAs and glycopyrronium, the inhibitory effect of these agents on tension and F340/F380 was evaluated using the BI theory, used previously to evaluate the synergistic effect of bronchodilators \[44,45\]. The main assumption of this model is that two or more agents act independently in terms of their sites of action \[46,47\]. The theory is represented by a very simple mathematical equation, and experimental data (from single points to entire dose–response curves) are applied to the equation to investigate synergy \[12,46,47\]. The relaxant effects of the SABAs procaterol (0.1–1 nM) and salbutamol (1–10 nM) in combination with glycopyrronium are greater than the expected values calculated by BI theory in equivalent concentrations of each agent (Figures 4 and 5). These results demonstrate that the combination of SABAs with glycopyrronium synergistically inhibits muscarinic contraction. However, the reduction in F340/F380 ratio by procaterol (0.1–1 nM) and salbutamol (1–10 nM) in the presence of glycopyrronium is not greater than the sum of the effect of equivalent concentrations of each agent or the values
calculated by BI theory in equivalent concentrations of each agent (Figures 4 and 5). These results demonstrate that an inhibition in Ca\(^{2+}\) sensitization contributes to this synergistic effect of SABAs with LAMAs against muscarinic contraction in airway smooth muscle.

As described above, given that contractile agonists, which stimulate GPCRs, activate RhoA and PKC, this indicates that Ca\(^{2+}\) sensitization via RhoA/Rho-kinase or PKC/CPI-17 processes is involved in the mechanism underlying the synergistic effect between these receptors. The inhibitory effect of a combination of SABAs with glycopyrronium in tension and F340/F380 is mimicked by the addition of bisindolylmaleimide, a PKC antagonist, to glycopyrronium, but not by the addition of Y-27632, a Rho-kinase antagonist (Figures 5 and 6). These results demonstrate that an inhibition in PKC-induced Ca\(^{2+}\) sensitization is involved in this synergistic effect, whereas Rho-kinase-induced Ca\(^{2+}\) sensitization is not. This phenomenon is similar to that observed in a previous report showing that the SABA isoprenaline acts by inhibiting Ca\(^{2+}\) sensitization independently of RhoA/Rho-kinase processes [43]. Because muscarinic receptor agonists act on PKC, sensitivity to intracellular Ca\(^{2+}\) is augmented via activation of CPI-17, independent of RhoA/Rho-kinase processes. Activation of \(\beta_2\)-adrenoceptors by binding of agonists such as SABA causes an increase of PKA activity. CPI-17 may be inhibited by PKA-induced phosphorylation. As a result, PKC-induced Ca\(^{2+}\) sensitization is attenuated by PKA [48]. Although it is still unclear about involvement of \(\beta_2\)-adrenergic action in PKC-induced Ca\(^{2+}\) sensitization mediated by contractile agonists in airway smooth muscle, a recent report has demonstrated that PKA suppresses (phosphorylates) CPI-17 in endothelial cells [49]. This finding may support our data that \(\beta_2\)-adrenergic relaxation is mediated by an inhibition of PKC-induced Ca\(^{2+}\) sensitization. Hence, PKC could be a target protein for the cross talk based on Ca\(^{2+}\) sensitization between \(\beta_2\)-adrenoceptors and muscarinic receptors. From results of our study, SABA may attenuate PKC-induced Ca\(^{2+}\)-sensitization via activation of PKA. To clarify this phenomenon, further investigation will be needed.

Although muscarinic receptor activation causes contraction by increasing both Ca\(^{2+}\) dynamics and Ca\(^{2+}\) sensitization [26,43], muscarinic blockade is mediated by affecting Ca\(^{2+}\) dynamics (reducing intracellular Ca\(^{2+}\) concentration), not by affecting Ca\(^{2+}\) sensitization (Figure 3). Hence, muscarinic receptor antagonists might enhance the relaxant effects of SABAs via mechanisms other than muscarinic blockade-induced Ca\(^{2+}\) dynamics. LAMAs may act on \(\beta_2\)-adrenoceptors via PKC-induced Ca\(^{2+}\) sensitization, leading to this synergistic effect between these two receptors [38]. Given that \(K_{\text{Ca}}\) channel activity plays an important role in the functional antagonism between \(\beta_2\)-adrenoceptors and muscarinic receptors [22], intracellular processes concerning these channels may be involved in this synergistic effect [17,18,20,22,50]. The G protein/\(K_{\text{Ca}}\) channel processes may contribute to an increase in response to muscarinic receptor agonists (airway hyperresponsiveness) [22,23] and a decrease in response to \(\beta_2\)-adrenoceptor agonists (\(\beta_2\)-adrenoceptor desensitization) [51,52]. We examined involvement of these processes in this synergistic effect. In the presence of iberiotoxin, a selective \(K_{\text{Ca}}\) channel inhibitor, the relaxant effects of the SABA/glycopyrronium combination were markedly attenuated with an increase in F340/F380 (Figure 7). As shown in Figures 4–6, Ca\(^{2+}\) dynamics might not be involved in the synergistic effect between SABAs and glycopyrronium. However, these results indicate that a reduction in intracellular Ca\(^{2+}\) concentration by \(K_{\text{Ca}}\) channel activation also causes this synergistic effect between these two receptors (Figure 1), consistent with the combination of indacaterol with glycopyrronium [9,10]. Because the outward currents are markedly increased by \(K_{\text{Ca}}\) channel opening, the membrane potential is hyperpolarized, leading to decreasing voltage-dependent Ca\(^{2+}\) entry (VDCE), such as L-type voltage-dependent Ca\(^{2+}\) channels [9,10,23] (Figure 1). Therefore, an inhibition in the \(G_{\text{i}}/K_{\text{Ca}}\) channel inhibitory linkage and an augmentation in the \(G_{\text{s}}/K_{\text{Ca}}\) channel stimulatory linkage are thought to be another functional intracellular mechanism of this synergistically relaxant effect of combination of \(\beta_2\)-adrenoceptor agonists with muscarinic receptor antagonists. \(K_{\text{Ca}}\) channels also could be a target protein for the cross talk based on Ca\(^{2+}\) dynamics between these two GPCRs.
4. Experimental Section

4.1. Tissue Preparation and Bathing Solution

Tracheae were excised from male Hartley guinea pigs (300–350 g) after intraperitoneal injection of pentobarbital (150 mg/kg). The tracheal rings were opened by cutting longitudinally at the cartilaginous region, and the epithelium was peeled off carefully. Normal bathing solution (in mM: NaCl 137, KHCO$_3$ 5.9, CaCl$_2$ 2.4, MgCl$_2$ 1.2, and glucose 11.8) bubbled with a mixture of 99% O$_2$ and 1% CO$_2$ (pH 7.4) was perfused at a constant flow of 4 mL/min. Organ bath temperature was maintained at 37 °C. The animal protocols used in this work were evaluated and approved by the Research Center for Animal Life Science Committee, Shiga University of Medical Science (identification code: 2013-4-1, 15 April 2013).

4.2. Isometric Tension Recording and Measurement of Fura-2 Fluorescence

This was conducted as described previously [26,43,53]. In brief, muscle strips were incubated with 15 µM fura-2/AM for about 2 h at room temperature (22–24 °C). The non-cytotoxic detergent Pluronic F-127 (0.01% w/v) was added to increase the solubility of fura-2/AM. After the fura-2/AM had penetrated the tissue, the experimental chamber was filled with normal bathing solution. Isometric tension and fura-2 fluorescence of muscle strips were measured simultaneously, using a displacement transducer and a spectrofluorometer (CAF-110, Japan Spectroscopic, Tokyo, Japan). The mucosal side of the smooth muscle was exposed to excitation light, and the intensities of excitation fluorescence at 340 nm and 380 nm were measured after background subtraction. Because the dissociation constant of fura-2 for Ca$^{2+}$ in smooth muscle cytoplasm was shown to be different from that measured in vitro, the absolute amount of intracellular Ca$^{2+}$ concentration was not calculated [54]. Therefore, the ratio of F340 to F380 (F340/F380) was used as a relative indicator of intracellular Ca$^{2+}$ concentration. Methacholine (MCh, 1 µM) was administered for 5 min at 10 min intervals until the control response to 1 µM MCh was established, and then the experiment was started. Muscle tension and F340/F380 in the resting state were taken as 0%, and the value of percent inhibition of tension and F340/F380 were measured taking the control response to MCh (1 µM) as 100%. Indomethacin (2 µM) was administered throughout the experiments to abolish resting tone.

4.3. Experimental Protocol

To examine the relationship between muscle tone and intracellular Ca$^{2+}$ concentration in the presence of β$_2$-adrenoceptor agonists or muscarinic receptor antagonists, procaterol (0.1–10 nM), salbutamol (1–100 nM) or glycopyrronium (0.3–10 nM) were each administered cumulatively to tissue precontracted with MCh (1 µM throughout the study). To examine this relationship in the presence of a combination of β$_2$-adrenoceptor agonists and muscarinic receptor antagonists, procaterol (0.1–1 nM) and salbutamol (1–10 nM) were added to MCh-precontracted tissue in the presence of glycopyrronium (3 nM), and procaterol (0.3–1 nM) was added to MCh-precontracted tissue in the presence of tiotropium (1 nM). To investigate the role of Ca$^{2+}$ dynamics due to KCa channel activity in the synergistic effects of β$_2$-adrenoceptor agonists and muscarinic receptor antagonists, procaterol and glycopyrronium were added together to MCh-precontracted tissue, in the presence of iberiotoxin (30 nM), a selective inhibitor of KCa channels, which are densely distributed on airway smooth muscle cell membrane [55]. Moreover, to investigate the role of Ca$^{2+}$ sensitization due to Rho-kinase and PKC in the synergistic effects of β$_2$-adrenoceptor agonists and muscarinic receptor antagonists, procaterol and glycopyrronium were both added to MCh-precontracted tissue in the presence of Y-27632 (1 µM), a selective inhibitor of Rho-kinase, and bisindolylmaleimide (10 µM), a potent inhibitor of PKC. Each reagent at each concentration was administered for 15 min (except MCh). Time-matched control tissues were treated similarly to the test tissues, but exposed continuously to the normal bathing solution (sham incubation) instead of procaterol, salbutamol, iberiotoxin, Y-27632, or bisindolylmaleimide.
4.4. Analysis of Synergistic Effect

The synergistic effect of glycopyrronium and procaterol or salbutamol and that of tiotropium and procaterol on contracted airway smooth muscle and change in intracellular Ca\(^{2+}\) concentration was evaluated using the BI theory. This model assumes that two or more agents act independently, with different modes and sites of action [46], and is expressed by the following equation:

\[
E(x, y) = E(x) + E(y) - E(x) \times E(y)
\]

where \(E\) is the fractional effect, and \(x\) and \(y\) are the doses of two compounds in a combination experiment. If the combined experimental value is higher than the expected value, the interaction is synergistic. If it is lower, the interaction is antagonistic [46,47].

4.5. Materials

MCh, indomethacin, procaterol, salbutamol, and glycopyrronium were obtained from Wako pure Chemical Industries (Osaka, Japan). Iberiotoxin was obtained from Peptide Institute (Osaka, Japan). Tiotropium, bisindolylmaleimide and Y-27632 were obtained from Sigma (St. Louis, MO, USA). Fura 2-AM was obtained from Dojin Laboratories (Kumamoto, Japan).

4.6. Statistical Analysis

All data are expressed as the mean ± standard deviation (SD). Statistical significance was assessed by \(t\)-test or Student’s unpaired \(t\)-test and one-way analysis of variance. \(p < 0.05\) was considered significant. Statistical analyses were performed using JMP version 11 (SAS Institute Inc., Cary, NC, USA).

![Figure 10](image-url). Clinical effectiveness of Combination of \(\beta_2\)-adrenoceptor agonists and muscarinic receptor antagonists is in the treatment for COPD via Ca\(^{2+}\) signaling (Ca\(^{2+}\) dynamics and Ca\(^{2+}\) sensitization). Since addition of \(\beta_2\)-adrenoceptor agonists to muscarinic receptor antagonists markedly enhance an inhibition of airway smooth muscle contraction, combination of these two agents are useful to suppression of excessive stimulation to muscarinic receptors induced by acetylcholine production in the airways, which is an fundamental characteristic for COPD. This phenomenon is due to cross talk between these two receptors via \(K_{Ca}\) channel-induced Ca\(^{2+}\) dynamics and PKC-induced Ca\(^{2+}\) sensitization in airway smooth muscle. Therefore, this combination therapy leads to reducing symptoms such as dyspnea on exertion and frequency of exacerbations, and to improving health status and lung function in patients with COPD.
5. Conclusions

The combination of β2-adrenoceptor agonists with muscarinic receptor antagonists causes a synergistic inhibition of muscarinic contraction in airway smooth muscle. Ca\(^{2+}\) signaling via PKC-induced Ca\(^{2+}\) sensitization and K\(_{\text{Ca}}\) channel-induced Ca\(^{2+}\) dynamics play a functional role in this synergistic effect (Figure 1). K\(_{\text{Ca}}\) channels and PKC are key protein for cross talk between β2-adrenoceptors and muscarinic receptors (Figure 10). Since it is generally considered that acetylcholine production (both neural and non-neural) in the airways is an essential pathophysiology for COPD, the effectiveness of therapy for this disease is depend on inhibitory action against excessive muscarinic stimulation. Hence, combination between these two agents is beneficial to reducing symptoms and exacerbations, and to improving health status and lung function (Figure 10). Our results provide further evidence that the combination of β2-adrenoceptor agents and anti-cholinergic agents are a promising advancement in bronchodilator therapy for COPD and asthma, and that PKC and K\(_{\text{Ca}}\) channels may be novel targets for bronchodilator research and development.

Acknowledgments: This work is supported by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (H.K. #25461201), and by Otsuka Pharmaceuticals (Tokyo, Japan).

Author Contributions: Kentaro Fukunaga, Hiroaki Kume and Tetsuya Oguma conceived and designed the experiments; Kentaro Fukunaga and Wataru Shigemori performed the experiments; Kentaro Fukunaga and Hiroaki Kume wrote the paper; Yasutaka Nakano, Emiko Ogawa and Yuji Tohda contributed reagents/materials/analysis tools.

Conflicts of Interest: This work was partly supported by Otsuka Pharmaceutical Co., Ltd. (Tokyo, Japan) (Hiroaki Kume, Tetsuya Oguma, Yasutaka Nakano). In addition, this study was funded, in part, by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (Hiroaki Kume #25461201). Otsuka Pharmaceutical Co., Ltd. (Tokyo, Japan) had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.

References

1. Barnes, P.J.; Shapiro, S.D.; Pauwels, R.A. Chronic obstructive pulmonary disease: Molecular and cellular mechanisms. Eur. Respir. J. 2003, 22, 672–688. [CrossRef] [PubMed]
2. The Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2016. Available online: http://goldcopd.org/ (accessed on 15 May 2016).
3. O’Donnell, D.E.; Revill, S.M.; Webb, K.A. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001, 164, 770–777. [CrossRef] [PubMed]
4. O’Donnell, D.E.; Laveneneziana, P. The clinical importance of dynamic lung hyperinflation in COPD. COPD J. Chronic Obstr. Pulm. Dis. 2006, 3, 219–232. [CrossRef] [PubMed]
5. Tashkin, D.P.; Celli, B.; Senn, S.; Burkhart, D.; Kesten, S.; Menjoge, S.; Decramer, M. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008, 359, 1543–1554. [CrossRef] [PubMed]
6. Trivedi, R.; Richard, N.; Mehta, R.; Church, A. Umeclidinium in patients with COPD: A randomized, placebo-controlled study. Eur. Respir. J. 2014, 43, 72–81. [CrossRef] [PubMed]
7. Donohue, J.F.; Fogarty, C.; Lotvall, J.; Mahler, D.A.; Worth, H.; Yorgancioglu, A.; Iqbal, A.; Swales, J.; Owen, R.; Higgins, M.; et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: Indacaterol versus tiotropium. Am. J. Respir. Crit. Care Med. 2010, 182, 155–162. [CrossRef] [PubMed]
8. Hanania, N.A.; Feldman, G.; Zachgo, W.; Shim, J.J.; Crim, C.; Sanford, L.; Lettis, S.; Barnhart, F.; Haumann, B. The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: A randomized placebo-controlled trial. Chest 2012, 142, 119–127. [CrossRef] [PubMed]
9. Kume, H. Ca\(^{2+}\) dynamics and Ca\(^{2+}\) sensitization in the regulation of airway smooth muscle tone. In Muscle Cell and Tissue; Sakuma, K., Ed.; INTECH: Rijeka, Croatia, 2015; pp. 289–330.
10. Kume, H.; Fukunaga, K.; Oguma, T. Research and development of bronchodilators for asthma and COPD with a focus on G protein/K\(_{\text{Ca}}\) channel linkage and β2-adrenergic intrinsic efficacy. Pharmacol. Ther. 2015, 156, 75–89. [CrossRef] [PubMed]
11. Dale, P.R.; Cernecka, H.; Schmidt, M.; Dowling, M.R.; Charlton, S.J.; Pieper, M.P.; Michel, M.C. The pharmacological rationale for combining muscarinic receptor antagonists and β-adrenergic agonists in the treatment of airway and bladder disease. Curr. Opin. Pharmacol. 2014, 16, 31–42. [CrossRef] [PubMed]

12. Calzetta, L.; Matera, M.G.; Cazzola, M. Pharmacological interaction between LABAs and LAMAs in the airways: Optimizing synergy. Eur. J. Pharmacol. 2015, 761, 168–173. [CrossRef] [PubMed]

13. Bateman, E.D.; Mahler, D.A.; Vogelmeier, C.F.; Wedzicha, J.A.; Patalano, F.; Banerji, D. Recent advances in COPD disease management with fixed-dose long-acting combination therapies. Expert Rev. Respir. Med. 2014, 8, 357–379. [CrossRef] [PubMed]

14. Wedzicha, J.A.; Decramer, M.; Ficker, J.H.; Niewoehner, D.E.; Sandstrom, T.; Taylor, A.F.; D’Andrea, P.; Arrasate, C.; Chen, H.; Banerji, D. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): A randomised, double-blind, parallel-group study. Lancet Respir. Med. 2013, 1, 199–209. [CrossRef] [PubMed]

15. Decramer, M.; Anzueto, A.; Kerwin, E.; Kaelin, T.; Richard, N.; Crater, G.; Tabberer, M.; Harris, S.; Church, A. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: Results from two multicentre, blinded, randomised controlled trials. Lancet Respir. Med. 2014, 2, 472–486. [CrossRef] [PubMed]

16. Bulh, R.; Maltais, F.; Aragh, R.; Bjermer, L.; McGarvey, L.; Hebert, J.; Harris, S.; Calzetta, L.; Matera, M.G.; Cazzola, M. Pharmacological interaction between LABAs and LAMAs in the treatment of chronic obstructive pulmonary disease (GOLD 2-4). Eur. Respir. J. 2015, 45, 969–979. [CrossRef] [PubMed]

17. Kume, H.; Hall, I.P.; Washabau, R.J.; Takagi, K.; Kotlikoff, M.I. β-adrenergic agonists regulate KCa channels in airway smooth muscle by cAMP-dependent and -independent mechanisms. J. Clin. Investig. 1994, 93, 371–379. [CrossRef] [PubMed]

18. Kume, H.; Graziano, M.P.; Kotlikoff, M.I. Stimulatory and inhibitory regulation of calcium-activated potassium channels by guanine nucleotide-binding proteins. Proc. Natl. Acad. Sci. USA 1992, 89, 11051–11055. [CrossRef] [PubMed]

19. Kotlikoff, M.I. Potassium channels in airway smooth muscle: A tale of two channels. Pharmacol. Ther. 1993, 58, 1–12. [CrossRef]

20. Kume, H.; Kotlikoff, M.I. Muscarinic inhibition of single KCa channels in smooth muscle cells by a pertussis-sensitive G protein. Am. J. Physiol. 1991, 261, C1204–C1209. [PubMed]

21. Semenov, I.; Nimmagadda, D.; Xu, X.; O’Rourke, S.T. Large-conductance, calcium-activated potassium channels: Structural and functional implications. Pharmacol. Ther. 2006, 110, 103–116. [CrossRef] [PubMed]

22. Semenov, I.; Wang, B.; Herlihy, J.T.; Brenner, R. BK channel β1 subunits regulate airway contraction secondary to M2 muscarinic acetylcholine receptor mediated depolarization. J. Physiol. 2011, 589, 1803–1817. [CrossRef] [PubMed]

23. Kume, H.; Mikawa, K.; Takagi, K.; Kotlikoff, M.I. Role of G proteins and KCa channels in the muscarinic and β-adrenergic regulation of airway smooth muscle. Am. J. Physiol. 1995, 268, L221–L229. [PubMed]

24. Kume, H.; Ishikawa, K.; Oguma, T.; Ito, S.; Shimokata, K.; Kotlikoff, M.I. Involvement of Ca2+ sensitization and mobilization by MCh in tracheal smooth muscle. J. Gen. Physiol. 1999, 114, 1039–1055. [CrossRef] [PubMed]

25. Kume, H.; Ishikawa, K.; Oguma, T.; Ito, S.; Shimokata, K.; Kotlikoff, M.I. Involvement of Ca2+ sensitization and mobilization by MCh in tracheal smooth muscle. J. Gen. Physiol. 2001, 165–178. [CrossRef] [PubMed]

26. Yoshimi, T.; Dibashi, K.; Horie, T.; Harada, T.; Nakazawa, T.; Mori, M. Relaxation of contracted rabbit tracheal and human bronchial smooth muscle by Y-27632 through inhibition of Ca2+ sensitization. Am. J. Respir. Cell Mol. Biol. 1999, 20, 1190–1200. [CrossRef] [PubMed]

27. Uehata, M.; Iizuka, K.; Dobashi, K.; Horie, T.; Harada, T.; Nakazawa, T.; Mori, M. Relaxation of contracted rabbit tracheal and human bronchial smooth muscle by Y-27632 through inhibition of Ca2+ sensitization. Am. J. Respir. Cell Mol. Biol. 1999, 20, 1190–1200. [CrossRef] [PubMed]

28. Uehata, M.; Iizuka, K.; Dobashi, K.; Horie, T.; Harada, T.; Nakazawa, T.; Mori, M. Relaxation of contracted rabbit tracheal and human bronchial smooth muscle by Y-27632 through inhibition of Ca2+ sensitization. Am. J. Respir. Cell Mol. Biol. 1999, 20, 1190–1200. [CrossRef] [PubMed]

29. Mukherjee, S.; Trice, J.; Shinde, P.; Willis, R.E.; Pressley, T.A.; Perez-Zoghbi, J.F. Ca2+ oscillations, Ca2+ sensitization, and contraction activated by protein kinase C in small airway smooth muscle. J. Gen. Physiol. 2013, 141, 165–178. [CrossRef] [PubMed]
30. Dixon, R.E.; Santana, L.F. A Ca\(^{2+}\)- and PKC-driven regulatory network in airway smooth muscle. *J. Gen. Physiol.* 2013, 141, 161–164. [CrossRef] [PubMed]

31. Bai, Y.; Sanderson, M.J. The contribution of Ca\(^{2+}\) signaling and Ca\(^{2+}\) sensitivity to the regulation of airway smooth muscle contraction is different in rats and mice. *Am. J. Physiol. Lung Cell. Mol. Physiol.* 2009, 296, L947–L958. [CrossRef] [PubMed]

32. Kume, H. RhoA/Rho-kinase as a therapeutic target in asthma. *Curr. Med. Chem.* 2008, 15, 2876–2885. [CrossRef] [PubMed]

33. Mahn, K.; Ojo, O.O.; Chadwick, G.; Aaronson, P.I.; Ward, J.P.; Lee, T.H. Ca\(^{2+}\) homeostasis and structural and functional remodelling of airway smooth muscle in asthma. *Thorax* 2010, 65, 547–552. [CrossRef] [PubMed]

34. Koopmans, T.; Anaparti, V.; Castro-Piedras, I.; Yarova, P.; Irecukwu, N.; Nelson, C.; Perez-Zoghbi, J.; Tan, X.; Ward, J.P.; Wright, D.B. Ca\(^{2+}\) handling and sensitivity in airway smooth muscle: Emerging concepts for mechanistic understanding and therapeutic targeting. *Palm. Pharmacol. Ther.* 2014, 29, 108–120. [CrossRef] [PubMed]

35. Taki, F.; Kume, H.; Kobayashi, T.; Ohta, H.; Aratake, H.; Shimokata, K. Effects of Rho-kinase inactivation on eosinophilia and hyper-reactivity in murine airways by allergen challenges. *Clin. Exp. Allergy* 2007, 37, 599–607. [CrossRef] [PubMed]

36. Gosens, R.; Schaafsma, D.; Meurs, H.; Zaagsma, J.; Nelemans, S.A. Role of Rho-kinase in maintaining airway smooth muscle contractile phenotype. *Eur. J. Pharmacol.* 2004, 483, 71–78. [CrossRef] [PubMed]

37. Schaafsma, D.; Gosens, R.; Zaagsma, J.; Halayko, A.J.; Meurs, H. Rho kinase inhibitors: A novel therapeutical perspective. *Toxicol. in Vitro* 2007, 21, 759–769. [CrossRef] [PubMed]

38. Kojima, K.; Kume, H.; Ito, S.; Yamaki, K.; Katoh, H.; Honjo, H.; Kodama, I.; Hayashi, H. Regulation of capacitative and noncapacitative receptor-operated Ca\(^{2+}\) entry by Rho-kinase in tracheal smooth muscle. *Am. J. Respir. Cell Mol. Biol.* 2002, 26, 491–498. [CrossRef] [PubMed]

39. Ito, S.; Kume, H.; Yamaki, K.; Katob, H.; Honjo, H.; Kodama, I.; Hayashi, H. Regulation of capacitative and noncapacitative receptor-operated Ca\(^{2+}\) entry by Rho-kinase in tracheal smooth muscle. *Am. J. Respir. Cell Mol. Biol.* 2002, 26, 491–498. [CrossRef] [PubMed]

40. Kojima, K.; Kume, H.; Ito, S.; Oguma, T.; Shiraki, A.; Kondo, M.; Ito, Y.; Shimokata, K. Direct effects of hydrogen peroxide on airway smooth muscle tone: Roles of Ca\(^{2+}\) influx and Rho-kinase. *Eur. J. Pharmacol.* 2007, 556, 151–156. [CrossRef] [PubMed]

41. Kume, H.; Takeda, N.; Oguma, T.; Ito, S.; Kondo, M.; Ito, Y.; Shimokata, K. Sphingosine 1-phosphate causes airway hyper-reactivity by Rho-mediated myosin phosphatase inactivation. *J. Pharmacol. Exp. Ther.* 2007, 320, 766–773. [CrossRef] [PubMed]

42. Shiraki, A.; Kume, H.; Oguma, T.; Makino, Y.; Ito, S.; Shimokata, K.; Honjo, H.; Kamiya, K. Role of Ca\(^{2+}\) mobilization and Ca\(^{2+}\) sensitization in 8-iso-PGF\(_{2\alpha}\)-induced contraction in airway smooth muscle. *Clin. Exp. Allergy* 2009, 39, 236–245. [CrossRef] [PubMed]

43. Oguma, T.; Kume, H.; Ito, S.; Takeda, N.; Horjo, H.; Kodama, I.; Shimokata, K.; Kamiya, K. Involvement of reduced sensitivity to Ca\(^{2+}\) in β-adrenergic action on airway smooth muscle. *Clin. Exp. Allergy* 2006, 36, 183–191. [CrossRef] [PubMed]

44. Cazzola, M.; Calzetta, L.; Page, C.P.; Rogliani, P.; Facciolo, F.; Gavalda, A.; Matera, M.G. Pharmacological characterization of the interaction between acilinium bromide and formoterol fumarate on human isolated bronchi. *Eur. J. Pharmacol.* 2014, 745, 135–143. [CrossRef] [PubMed]

45. Cazzola, L.; Page, C.P.; Spina, D.; Cazzola, M.; Rogliani, P.; Facciolo, F.; Matera, M.G. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. *J. Pharmacol. Exp. Ther.* 2013, 346, 414–423. [CrossRef] [PubMed]

46. Greco, W.R.; Bravo, G.; Parsons, J.C. The search for synergy: A critical review from a response surface perspective. *Pharmacol. Rev.* 1995, 47, 331–385. [PubMed]

47. Goldoni, M.; Johansson, C. A mathematical approach to study combined effects of toxicants in vitro: Evaluation of the bliss independence criterion and the loewe additivity model. *Toxicol. in Vitro* 2007, 21, 759–769. [CrossRef] [PubMed]

48. Pera, T.; Penn, R.B. Crosstalk between β-2-adrenoceptor and muscarinic acetylcholine receptors in the airway. *Curr. Opin. Pharmacol.* 2014, 16, 72–81. [CrossRef] [PubMed]
49. Aslam, M.; Hartel, F.V.; Arshad, M.; Gunduz, D.; Abdallah, Y.; Sauer, H.; Piper, H.M.; Noll, T. cAMP/PKA antagonizes thrombin-induced inactivation of endothelial myosin light chain phosphatase: Role of CPI-17. Cardiovasc. Res. 2010, 87, 375–384. [CrossRef] [PubMed]

50. Kume, H.; Takai, A.; Tokuno, H.; Tomita, T. Regulation of Ca²⁺-dependent K⁺-channel activity in tracheal myocytes by phosphorylation. Nature 1989, 341, 152–154. [CrossRef] [PubMed]

51. Kume, H.; Takagi, K. Inhibitory effects of Gs on desensitization of β-adrenergic receptors in tracheal smooth muscle. Am. J. Physiol. 1997, 273, L556–L564. [PubMed]

52. Kume, H.; Takagi, K. Inhibition of β-adrenergic desensitization by K⁺Ca channels in human trachealis. Am. J. Respir. Crit. Care Med. 1999, 159, 452–460. [CrossRef] [PubMed]

53. Satake, K.; Takagi, K.; Kodama, I.; Honjo, H.; Toyama, J.; Shibata, S. Relaxant effects of NKH477, a new water-soluble forskolin derivative, on guinea-pig tracheal smooth muscle: The role of Ca²⁺-activated K⁺ channels. Br. J. Pharmacol. 1998, 123, 753–761. [CrossRef] [PubMed]

54. Konishi, M.; Olson, A.; Hollingworth, S.; Baylor, S.M. Myoplasmic binding of fura-2 investigated by steady-state fluorescence and absorbance measurements. Biophys. J. 1988, 54, 1089–1104. [CrossRef]

55. Kume, H.; Takagi, K.; Satake, T.; Tokuno, H.; Tomita, T. Effects of intracellular pH on calcium-activated potassium channels in rabbit tracheal smooth muscle. J. Physiol. 1990, 424, 445–457. [CrossRef] [PubMed]

© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).